Evaluating the Efficacy of Lymphocyte Immunization Therapy in Improving Ongoing Pregnancy Rates in Women with Recurrent Pregnancy Loss and Implantation Failure: A Prospective Interventional Single Arm Study

This prospective interventional study evaluates the efficacy of Lymphocyte Immunotherapy (LIT) in enhancing ongoing pregnancy rates in women with unexplained recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF), focusing on immune profile changes, particularly Treg levels and the Th1/Th2 cytokine balance. Inclusion criteria include RPL or RIF with unexplained infertility, high HLA match (≥2 alleles, especially HLA-C), and negative CDC cross-match and ANA, while exclusions cover uncorrected endocrine issues, uterine anomalies, thin endometrium (<7mm), APLA positivity, untreated chronic endometritis, refusal of immunology evaluation, and Grade C/D embryo transfers. Lymphocytes, sourced from paternal or third-party donors, are isolated through density gradient centrifugation. The LIT procedure involves subcutaneous injections in the maternal forearm, typically administered twice preconception and once in early pregnancy, with patients monitored for immediate reactions and followed up regularly to assess immune response and progress.